[
  {
    "ts": null,
    "headline": "FDA to review Regeneron’s sBLA for aflibercept injection 8mg",
    "summary": "The application is based on data from the Eylea HD clinical programme, including the Phase III QUASAR trial.",
    "url": "https://finnhub.io/api/news?id=e92880dcf03e80499ed9d2b5af7bdd058e438442652de3d48631b73cdd39e6b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744899909,
      "headline": "FDA to review Regeneron’s sBLA for aflibercept injection 8mg",
      "id": 133958750,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The application is based on data from the Eylea HD clinical programme, including the Phase III QUASAR trial.",
      "url": "https://finnhub.io/api/news?id=e92880dcf03e80499ed9d2b5af7bdd058e438442652de3d48631b73cdd39e6b2"
    }
  },
  {
    "ts": null,
    "headline": "EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications",
    "summary": "If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated for all other anti-VEGF therapies Potential for as frequent as monthly dosing for all approved indications would provide greater dosing flexibility for physicians and patients TARRYTOWN, N.Y., April 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the",
    "url": "https://finnhub.io/api/news?id=ccee2e210dbd219eb15f78cdf5f8f11decc1355de96a85e4e7dd8ad2700b2251",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744887600,
      "headline": "EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications",
      "id": 133942732,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated for all other anti-VEGF therapies Potential for as frequent as monthly dosing for all approved indications would provide greater dosing flexibility for physicians and patients TARRYTOWN, N.Y., April 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the",
      "url": "https://finnhub.io/api/news?id=ccee2e210dbd219eb15f78cdf5f8f11decc1355de96a85e4e7dd8ad2700b2251"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Gets FDA Priority Review for Expanded Eylea HD Use",
    "summary": "By Colin Kellaher Regeneron Pharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Eylea HD eye drug. Regeneron on...",
    "url": "https://finnhub.io/api/news?id=d7962718a0e1637a7dcfcc4a14712dcdfbc4d7accaf3070aecbcad67406ed0c8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744876931,
      "headline": "Regeneron Gets FDA Priority Review for Expanded Eylea HD Use",
      "id": 133942070,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Regeneron Pharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Eylea HD eye drug. Regeneron on...",
      "url": "https://finnhub.io/api/news?id=d7962718a0e1637a7dcfcc4a14712dcdfbc4d7accaf3070aecbcad67406ed0c8"
    }
  }
]